Financial press releases
Development of NanoManganese for the optimization of radiotherapy in cancer treatment – April 20, 2022
2021 full-year business and earnings – April 13, 2022
Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy – April 5, 2022
U.S. patent protection registration of the future drug allowing the decorporation of cesium – March 24, 2022
Medesis Pharma confirms its eligibility for the PEA-PME – January 14, 2022
Medesis Pharma presents a scientific poster at the Congress on Gene Therapy for the Treatment of Neurological Diseases – December 2, 2021
Treatment of severe forms of Covid-19: Medesis Pharma phase II clinical study authorized by Brazilian health authorities – November 22, 2021
Treatment of Alzheimer disease : Medesis Pharma phase II clinical study authorized by ANSM (Agence nationale de sécurité du médicament et des produits de santé; France) – September 21, 2021
Half-year activities and results – September 16, 2021
Medesis Pharma files a European patent with TRANSGENE, the result of their joint work – September 1, 2021
Repositioning of the NanoManganese program outside the EU after an ANSM refusal – August 26, 2021
Report of the Combined General Meeting – June 15, 2021
Drug candidate development plan for treatment of Huntington disease receives favorable opinion from the EMA – June 3, 2021
Initiation of analyst coverage by Invest Securities – May 7, 2021
Availability of the 2020 Annual Financial Report – April 28, 2021
Annual results and outlook for 2021
Description of the share buyback program and implementation of a liquidity contract – March 12, 2021
Medesis Pharma raises € 7.35m following the very successful IPO on Euronext Paris – February 10, 2021
Medesis Pharma launches its IPO on Euronext Growth Paris – January 26, 2021